Clinical trial · Interventional
Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer
NCT00049790CI-TRIAL-00001878completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin | Drug | Carboplatin | ALIAS |
| paclitaxel | Drug | Paclitaxel | ALIAS |
| recombinant human Angiostatin protein | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion: * Histological or cytological confirmed Stage IIIB NSCLC with malignant pleural effusions, or Stage IV NSCLC or recurrent NSCLC * No previous chemotherapy for NSCLC * Have one lesion that is bidimensionally measurable by physical exam, MRI, or CT greater than 1 cm in diameter * Specified lab parameters * Life expectancy of at least 12 weeks * ECOG performance status of 0 or 1 * Understand requirements of study * Agree to use effective contraceptive methods Exclusion: * Have CNS metastases * Have any active cancer in addition ot NSCLC * Participated in clinical trial involving conventional or investigational drugs within previous 4 weeks * Have any contraindication to paclitaxel or carboplatin * Have had Grade 3 or greater peripheral neuropathies * Be pregnant or lactating * Have a history of myocardial infarction or angina pectoris/angina in the last 6 months * Have had significant (30 mL or more) hemoptysis with the past 3 months * Have an active infection * Have a history of bleeding diathesis, hypercoagulable condition, or an active bleeding disorder * Be receiving concurrent treatment with therapeutic doses of heparin or coumadin * Have had major surgery within 4 weeks of stating therapy * Have additional uncontrolled serious medical conditions or psychiatric illness * Received rhAngiostatin in other clinical protocols
References
Publications (0)
Data not yet available
No reference posted for this study.